Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

View More View Less
  • a Division of Surgical Oncology, Department of Surgery, and Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, Texas.

Background: Preoperative therapy is being increasingly used in the treatment of resectable pancreatic cancer. Because there are only limited data on the optimal preoperative regimen, we compared overall survival (OS) between preoperative chemotherapy (CT) and preoperative chemoradiotherapy (CRT) in resectable pancreatic adenocarcinoma. Patients and Methods: Patients receiving preoperative therapy and resection for clinical T1–3N0–1M0 adenocarcinoma of the pancreas were identified in the National Cancer Database for 2006 through 2012. We constructed inverse probability of treatment weights to balance baseline group differences, and compared OS between CT and CRT, as well as pathologic and postoperative findings. Results: We identified 1,326 patients (CT: 616; CRT: 710). Differences in OS were not significant between CRT and CT (median survival, 25 vs 26 months; P=.10; weight-adjusted hazard ratio, 0.89; 95% CI, 0.77–1.02). Compared with patients in the CT group, those in the CRT group had lower pathologic T stage (ypT0/T1/T2: 36% vs 21%; P<.01), less lymph node involvement (ypN1: 35% vs 59%; P<.01), and fewer positive resection margins (14% vs 21%; P=.01), but had more postoperative unplanned readmissions (9% vs 6%; P=.01) and increased 90-day mortality (7% vs 4%; P=.03). Those in the CRT group were also less likely to receive postoperative therapy (26% vs 51%; P<.01). Conclusions: Preoperative CT and CRT have similar OS, but CRT is associated with more favorable pathologic features at the cost of higher postoperative morbidity and mortality. Additional trials investigating preoperative therapy are needed for patients with resectable pancreatic cancer.

Author contributions: Study concept and methodology: All authors. Analysis and interpretation of results: All authors. Manuscript preparation: Mokdad, Polanco. Critical revision: All authors.

Correspondence: Patricio M. Polanco, MD, Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8548. Email: Patricio.Polanco@utsouthwestern.edu
  • 1.

    Gillen S, Schuster T, Meyer Zum Büschenfelde C et al.. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.

    • Search Google Scholar
    • Export Citation
  • 2.

    Neoptolemos JP, Stocken DD, Friess H et al.. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:12001210.

    • Search Google Scholar
    • Export Citation
  • 3.

    Oettle H, Post S, Neuhaus P et al.. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267277.

    • Search Google Scholar
    • Export Citation
  • 4.

    Neoptolemos JP, Palmer DH, Ghaneh P et al.. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:10111024.

    • Search Google Scholar
    • Export Citation
  • 5.

    Tempero MA, Malafa MP, AL-Hawary M et al.. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2017. Accessed January 22, 2016. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 6.

    Tzeng CW, Tran Cao HS, Lee JE et al.. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 2014;18:1624; discussion 24–25.

    • Search Google Scholar
    • Export Citation
  • 7.

    Aloia TA, Aloia TE, Lee JE et al.. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 2007;204:347355.

    • Search Google Scholar
    • Export Citation
  • 8.

    Mayo SC, Gilson MM, Herman JM et al.. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg 2012;214:3345.

    • Search Google Scholar
    • Export Citation
  • 9.

    Mokdad AA, Minter RM, Zhu H et al.. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 2017;35:515522.

    • Search Google Scholar
    • Export Citation
  • 10.

    Klinkenbijl JH, Jeekel J, Sahmoud T et al.. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776782; discussion 782–784.

    • Search Google Scholar
    • Export Citation
  • 11.

    Boffa DJ, Rosen JE, Mallin K et al.. Using the National Cancer Database for outcomes research: a review. JAMA Oncol 2017;3:17221728.

  • 12.

    Ben-Josef E, Schipper M, Francis IR et al.. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;84:11661171.

    • Search Google Scholar
    • Export Citation
  • 13.

    Badiyan SN, Olsen JR, Lee AY et al.. Induction chemotherapy followed by concurrent full-dose gemcitabine and intensity-modulated radiation therapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2016;39:17.

    • Search Google Scholar
    • Export Citation
  • 14.

    Murphy JD, Adusumilli S, Griffith KA et al.. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801808.

    • Search Google Scholar
    • Export Citation
  • 15.

    Rich T, Harris J, Abrams R et al.. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004;27:5156.

    • Search Google Scholar
    • Export Citation
  • 16.

    Crane CH, Winter K, Regine WF et al.. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009;27:40964102.

    • Search Google Scholar
    • Export Citation
  • 17.

    Rich TA, Winter K, Safran H et al.. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Onco Targets Ther 2012;5:161170.

    • Search Google Scholar
    • Export Citation
  • 18.

    Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987;82:387394.

  • 19.

    Guo S, Fraser MW. Propensity Score Analysis: Statistical Methods and Applications. Thousand Oaks, CA: SAGE Publications, Inc.; 2014.

  • 20.

    Potter FJ. A study of procedures to identify and trim extreme sampling weights. In: Proceedings of the Survey Research Methods Section. Washington, DC: American Statistical Association; 1990:225230.

    • Search Google Scholar
    • Export Citation
  • 21.

    Wang R, Lagakos SW, Ware JH et al.. Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:21892194.

  • 22.

    White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30:377399.

  • 23.

    Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons; 2004.

  • 24.

    Conroy T, Desseigne F, Ychou M et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:18171825.

  • 25.

    Von Hoff DD, Ervin T, Arena FP et al.. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:16911703.

    • Search Google Scholar
    • Export Citation
  • 26.

    Von Hoff DD, Ramanathan RK, Borad MJ et al.. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:45484554.

    • Search Google Scholar
    • Export Citation
  • 27.

    Denbo JW, Bruno ML, Cloyd JM et al.. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg 2016;20:19751985.

    • Search Google Scholar
    • Export Citation
  • 28.

    Cooper AB, Parmar AD, Riall TS et al.. Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates? J Gastrointest Surg 2015;19:8086; discussion 86–87.

    • Search Google Scholar
    • Export Citation
  • 29.

    Cho SW, Tzeng CW, Johnston WC et al.. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford) 2014;16:350356.

    • Search Google Scholar
    • Export Citation
  • 30.

    Groot VP, Rezaee N, Wu W et al.. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 2018;267:936945.

    • Search Google Scholar
    • Export Citation
  • 31.

    Cloyd JM, Crane CH, Koay EJ et al.. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 2016;122:26712679.

    • Search Google Scholar
    • Export Citation
  • 32.

    Varadhachary GR, Wolff RA, Crane CH et al.. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:34873495.

    • Search Google Scholar
    • Export Citation
  • 33.

    Evans DB, Varadhachary GR, Crane CH et al.. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:34963502.

    • Search Google Scholar
    • Export Citation
  • 34.

    Katz MHG, Shi Q, Ahmad SA et al.. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology trial A021101. JAMA Surg 2016;151:e161137.

    • Search Google Scholar
    • Export Citation
  • 35.

    Iacobuzio-Donahue CA, Fu B, Yachida S et al.. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:18061813.

    • Search Google Scholar
    • Export Citation
  • 36.

    Gnerlich JL, Luka SR, Deshpande AD et al.. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg 2012;147:753760.

    • Search Google Scholar
    • Export Citation
  • 37.

    Tsai S, Evans DB. Therapeutic advances in localized pancreatic cancer. JAMA Surg 2016;151:862868.

  • 38.

    Merkow RP, Bilimoria KY, Tomlinson JS et al.. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014;260:372377.

    • Search Google Scholar
    • Export Citation
  • 39.

    Cloyd JM, Katz MH, Prakash L et al.. Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastrointest Surg 2017;21:164174.

    • Search Google Scholar
    • Export Citation
  • 40.

    Khorana AA, Mangu PB, Berlin J et al.. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016;34:25412556.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 33 0 0
Full Text Views 609 97 8
PDF Downloads 310 81 9
EPUB Downloads 0 0 0